Literature DB >> 24756053

Persistent congenital hyperinsulinism in two patients with Beckwith-Wiedemann syndrome due to mosaic uniparental disomy 11p.

Yuri A Zarate, Natasha Shur, Andrew Robin, Adolfo D Garnica, Jose Bernardo Quintos, G Bradley Schaefer.   

Abstract

Congenital hyperinsulinism (CHI) is a rare metabolic disease characterized by inappropriate insulin secretion in the presence of hypoglycemia. We describe the clinical presentation and management of congenital hyperinsulinism and persistent hypoglycemia in two infants. Both patients had an initial clinical diagnosis of Beckwith-Wiedemann syndrome (BWS) but normal methylation analysis for LIT1 and H19 status. Both patients were eventually found to have mosaic uniparental disomy 11p diagnosed by single nucleotide polymorphism (SNP) array in DNA isolated from lymphoblasts and fibroblasts, respectively. We report that patients with mosaic BWS are at increased risk for both transient and refractory hypoglycemia that may need aggressive management with diazoxide, octreotide, high glucose infusion rates, and a frequent feeding regime. Our patient experience supports the case for pursuing further testing in patients with features of BWS with normal methylation studies, karyotype, and SNP arrays on blood. The next logical step is SNP array on skin biopsy to rule out mosaicism.

Entities:  

Mesh:

Year:  2014        PMID: 24756053     DOI: 10.1515/jpem-2013-0484

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  3 in total

1.  Congenital hyperinsulinism in children with paternal 11p uniparental isodisomy and Beckwith-Wiedemann syndrome.

Authors:  Jennifer M Kalish; Kara E Boodhansingh; Tricia R Bhatti; Arupa Ganguly; Laura K Conlin; Susan A Becker; Stephanie Givler; Lindsey Mighion; Andrew A Palladino; N Scott Adzick; Diva D De León; Charles A Stanley; Matthew A Deardorff
Journal:  J Med Genet       Date:  2015-11-06       Impact factor: 6.318

Review 2.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565

3.  Successful use of long acting octreotide in two cases with Beckwith-Wiedemann syndrome and severe hypoglycemia.

Authors:  Hiba Al-Zubeidi; Michael E Gottschalk; Ron S Newfield
Journal:  Int J Pediatr Endocrinol       Date:  2014-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.